Early cancer detection firm Oncimmune Holdings announced on Monday that it has launched a liver cancer biopsy in the US using its EarlyCDT platform. The biopsy, which is the second product to be launched using the AIM traded company's EarlyCDT platform, is a test for hepatocellular carcinoma (HCC) with a specificity of 97%, meaning that results can be analysed with a "high degree of certainty" according to Oncimmune. Geoffrey Hamilton-Fairley, chief executive of Oncimmune, commented: "We are ...Den vollständigen Artikel lesen ...
© 2018 LiveCharts.co.uk
